BioCentury | Jun 6, 2019
Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

...who retired. Ronald Andrews will succeed William Annett as CEO of lung cancer diagnostic company OncoCyte Corp....
BioCentury | Feb 1, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. OncoCyte...
...study in 350 patient samples before it launches the product in the U.S. next half. OncoCyte...
...cell lung cancer (NSCLC). BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) holds about 36% of OncoCyte shares. OncoCyte Corp....
BioCentury | Jan 29, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...soaring $4.09 (225%) to $5.91. BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX), which holds about 36% of OncoCyte...
...$0.50 (55%) to $1.39 on NYSE-A and adding NIS104.10 (32%) to NIS428.80 in Tel Aviv. OncoCyte...
...study in 350 patient samples before it launches the product in the U.S. next half. OncoCyte...
BioCentury | Oct 12, 2015
Financial News

OncoCyte financial update

...OncoCyte Corp. , Alameda, Calif. Business: Cancer, Gene/Cell therapy Date announced: 2015-10-07 Note: OncoCyte, a majority-owned...
BioCentury | Jun 17, 2015
Company News

Management tracks

...Goodenow as CBO. He was CBO at Syndax Pharmaceuticals Inc. (Waltham, Mass.). Cancer diagnostics company OncoCyte Corp....
BioCentury | May 18, 2015
Financial News

OncoCyte completes venture financing

...million Investor: Existing investors Note: The company also converted $3.3 million of debt into equity. OncoCyte...
BioCentury | Feb 10, 2014
Clinical News

PanC-Dx: Clinical trial started

...bladder cancer diagnosis and from those with a risk for recurrent disease. In certain cases, OncoCyte's...
...late this year. OncoCyte Corp.'s parent company, BioTime Inc. (NYSE-M:BTX, Alameda Calif.) declined to disclose details. OncoCyte Corp....
BioCentury | Oct 21, 2013
Company News

BioTime, Wistar deal

...BioTime's OncoCyte Corp. subsidiary partnered with the institute to develop lung cancer diagnostic products. Wistar investigators are...
...assess gene expression patterns in blood cells of patients with malignant and non-malignant lung disease. OncoCyte...
...patients in the trial to determine levels of tumor-associated proteins using its PanC-Dx cancer diagnostic. OncoCyte...
BioCentury | Jan 30, 2012
Company News

BioTime, The Wistar Institute deal

...have shown that the gene has pivotal roles in cancer and stem cell biology. BioTime's OncoCyte Corp....
BioCentury | Jan 2, 2012
Company News

BioTime, USCN deal

...for large-scale manufacture of the antibody components of its PanC-Dx cancer diagnostic. BioTime and its OncoCyte Corp....
Items per page:
1 - 10 of 15
BioCentury | Jun 6, 2019
Company News

Management tracks: Grail taps Juno founder Bishop as CEO; plus Clovis, OncoCyte, Calico

...who retired. Ronald Andrews will succeed William Annett as CEO of lung cancer diagnostic company OncoCyte Corp....
BioCentury | Feb 1, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...and specificity of 75% in the prospective R&D Validation study in 250 patient blood samples. OncoCyte...
...study in 350 patient samples before it launches the product in the U.S. next half. OncoCyte...
...cell lung cancer (NSCLC). BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX) holds about 36% of OncoCyte shares. OncoCyte Corp....
BioCentury | Jan 29, 2019
Clinical News

OncoCyte's lung cancer liquid biopsy test shows 90% sensitivity

...soaring $4.09 (225%) to $5.91. BioTime Inc. (NYSE-A:BTX; Tel Aviv:BTX), which holds about 36% of OncoCyte...
...$0.50 (55%) to $1.39 on NYSE-A and adding NIS104.10 (32%) to NIS428.80 in Tel Aviv. OncoCyte...
...study in 350 patient samples before it launches the product in the U.S. next half. OncoCyte...
BioCentury | Oct 12, 2015
Financial News

OncoCyte financial update

...OncoCyte Corp. , Alameda, Calif. Business: Cancer, Gene/Cell therapy Date announced: 2015-10-07 Note: OncoCyte, a majority-owned...
BioCentury | Jun 17, 2015
Company News

Management tracks

...Goodenow as CBO. He was CBO at Syndax Pharmaceuticals Inc. (Waltham, Mass.). Cancer diagnostics company OncoCyte Corp....
BioCentury | May 18, 2015
Financial News

OncoCyte completes venture financing

...million Investor: Existing investors Note: The company also converted $3.3 million of debt into equity. OncoCyte...
BioCentury | Feb 10, 2014
Clinical News

PanC-Dx: Clinical trial started

...bladder cancer diagnosis and from those with a risk for recurrent disease. In certain cases, OncoCyte's...
...late this year. OncoCyte Corp.'s parent company, BioTime Inc. (NYSE-M:BTX, Alameda Calif.) declined to disclose details. OncoCyte Corp....
BioCentury | Oct 21, 2013
Company News

BioTime, Wistar deal

...BioTime's OncoCyte Corp. subsidiary partnered with the institute to develop lung cancer diagnostic products. Wistar investigators are...
...assess gene expression patterns in blood cells of patients with malignant and non-malignant lung disease. OncoCyte...
...patients in the trial to determine levels of tumor-associated proteins using its PanC-Dx cancer diagnostic. OncoCyte...
BioCentury | Jan 30, 2012
Company News

BioTime, The Wistar Institute deal

...have shown that the gene has pivotal roles in cancer and stem cell biology. BioTime's OncoCyte Corp....
BioCentury | Jan 2, 2012
Company News

BioTime, USCN deal

...for large-scale manufacture of the antibody components of its PanC-Dx cancer diagnostic. BioTime and its OncoCyte Corp....
Items per page:
1 - 10 of 15